Abstract

In the last 10 years local applications containing neomycin for the skin have been widely prescribed, and it has become evident that sensitisation is fairly common. More recently, framycetin (generally thought to be identical with neomycin B¹) has also been widely used, and many patients sensitive to it are cross-sensitive to neomycin.² The therapeutic uses of these drugs therefore need reassessment.